Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
July 17, 2023 at 10:15 AM EDT
Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.
